12 completed, 1 withdrawn. 7 Phase 3, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Respimat: new trials by email Literature Review of Respimat trials Research Report on Respimat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-usable Respimat® Soft MistTM Inhaler Study Respimat - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 262 | 2019-09-30 | 2021-03-03 | |
| Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge Tiotropium, glycopyrronium, Respimat - Asthma | Phase 4 | Completed | University of Saskatchewan | 13 | 2015-11-01 | 2016-04-20 |
| Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients Placebo, Tiotropium, Olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 295 | 2012-03-01 | 2015-09-15 |
| Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease tiotropium + olodaterol, tiotropium, olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 219 | 2012-03-01 | 2015-07-16 |
| Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. Placebo, Tiotropium + Olodaterol, tiotropium + Olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 291 | 2012-02-01 | 2015-09-15 |
| Japan Long-term Safety for Tiotropium Plus Olodaterol Tiotropium + Olodaterol, Respimat, Olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 122 | 2012-02-01 | 2015-07-15 |
| Olodaterol Bridging Study in Asthma Respimat, Olodaterol, Olodaterol & BI54903 - Asthma | Phase 2 | Withdrawn | Boehringer Ingelheim | 2011-10-01 | 2011-11-22 | |
| Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) tiotropium + olodaterol, tiotropium, olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 2624 | 2011-09-01 | 2015-07-16 |
| Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) tiotropium + olodaterol, tiotropium, olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 2539 | 2011-09-01 | 2015-07-16 |
| Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients tiotropium, Handihaler, Respimat - Chronic Obstructive Pulmonary Disease | Not applicable | Completed | University of Crete | 200 | 2010-03-01 | 2017-03-30 |
| Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) olodaterol (BI 1744) low, low tiotropium bromide, olodaterol (BI 1744) high - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 233 | 2010-01-01 | 2015-07-15 |
| Tiotropium / Respimat One Year Study in COPD. Respimat, Tiotropium - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 3991 | 2006-09-01 | 2014-05-16 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) Tiotropium 0.625 mcg/puff, Tiotropium 1.25 mcg/puff, Tiotropium 2.5 mcg/puff - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 202 | 1998-03-01 | 2025-01-31 |
Pulmonary Disease, Chronic Obstructive (11) · Asthma (2) · Sleep Initiation and Maintenance Disorders (1)
Boehringer Ingelheim (11) · University of Crete (1) · University of Saskatchewan (1)
Canada (8) · Germany (8) · Netherlands (6) · United States (6) · Belgium (4) · Denmark (4) · Hungary (4) · Sweden (4) · Argentina (3) · Australia (3) · Austria (3) · China (3) · Finland (3) · France (3) · India (3)
Don Cockcroft, MD (1) · Sophia E Schiza, MD, PhD (1)
PMID 32943047, PMID 25573406, PMID 26112656, PMID 27993292, PMID 28424359, PMID 29355547, PMID 30261995, PMID 32462607, PMID 32671684, PMID 32776202, PMID 32848379, PMID 32848380, PMID 33175291, PMID 20620037, PMID 25956072, PMID 26404912, PMID 27578477
2009 (3)